Should we implement 'opt-out' HIV testing for patients with lymphoma?

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 9, Issue 4, 2009, Pages 320-322

  Cave, Judith ^a   Edwards, S G ^b   Miller, R F ^c   Ardeshna, K M ^a   Lee, S M ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b Camden Primary Care Trust   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

HIV; Lymphoma; Screening

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CHILD; FEMALE; HEPATITIS B; HEPATITIS C; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; SCREENING TEST;

EID: 70249125117     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.9-4-320     Document Type: Article

References (10)

1. Dodds C, Weatherburn P. Reducing the length of time between HIV infection and diagnosis. BMJ 2007;334:1329-30.
2. Donaldson L, Beasley C. Improving the detection and diagnosis of HIV in non-HIV specialties including primary care. London: Department of Health, 2007.
3. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007;60:1365-72.
4. Kaplan LD, Lee JY, Ambinder RF et al. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS-malignancies consortium trial 010. Blood 2005;24:1538-43.
5. Navarro JT, Ribera JM, Oriol A et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001;112:909-15.
6. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002;137:435-78.
7. ESMO Guidelines Task Force. minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma. Ann Oncol 2001;12:1209-10.
8. Simpson WM, Johnstone FD, Boyd FM et al. Uptake and acceptability of antenatal HIV testing: Randomised controlled trial of different methods of offering the test. BMJ 1998;316:262-7.
9. Walmsley S. Opt in or opt out: What is optimal for prenatal screening for HIV infection? Can Med Assoc J 2003;168.
10. Branson BM, Handsfield HH, Lampe MA et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55(RR14);1-17.